



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, **Dimitrios Athanasiou**

Organisation/Company: World Duchenne Organisation

Country: Greece

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I am a volunteer in the board of World Duchenne Organization / UPPMD.
 UPPMD participates in Vision DMD a H2020 publicly funded research involving VBP-15 started in 2016 in which I am the project coordinator of UPPMD.
 UPPMD participates in Share4Rare a H2020 publicly funded research involved in patient data collection in Rare Diseases started in 2018 in which I am the project coordinator of UPPMD.
 UPPMD participates in Trials@Home an IMI publicly funded research involved in Remote and Decentralized Trials started in 2019 in which I am the project coordinator of UPPMD.
 I am a volunteer board member of EPF
 I was a volunteer member of the DIA/EFGCP's Pediatric Conference 2019 and 2020 organizing committee
 I am a volunteer trainer in European Patient Academy, Eurordis Open Academy, Duchenne Patient Academy
 I am a volunteer and a Duchenne Patient Representative in MDA Hellas and "95" Rare Alliance Greece Patient Representative

I am a volunteer in Eurordis

Subject matter -Name of companies

EURORDIS Round Table of Companies (ERTC) 2018
 ABLYNX, ACHILLION, ACTELION, AEGERION, AGIOS, AKARI THERAPEUTICS, AKCEA, ALEXION, ALNYLAM, AMGEN, AMICUS THERAPEUTICS, APOXIS, ARIAD, ASTRAZENECA, AUDENTES, AVEXIS, BAXALTA, BAXTER, BELLUS HEALTH, BAYER, BIOGEN, BIOMARIN, BLUEBIRD BIO, BOEHRINGER INGELHEIM, BRIDGEBIO, BRISTOL-MYERS SQUIBB, CELGENE, CHIESI, CLOVIS ONCOLOGY, CSL BEHRING, CYTOKINETICS, DIPHARMA, DOMPE, EDITAS, ENOBIA, ERYTECH, EUSA PHARMA, ENZYVANT, FOLDRX, GILEAD, GLOUCESTER PHARMACEUTICALS, GRIFOLS, GSK, GSK, HEALX, HELSINN, HORIZON, HRA PHARMA, ICON, IDM PHARMA, INCYTE, INSMED, INTERMUNE, IPSEN, JANSSEN, JAZZ PHARMA, JERINI, KYOWA KIRIN, LEADIANT BIOSCIENCES, LFB BIOMEDICAMENTS, LYSOGENE, MEDUNIK CANADA, MEREIO BIOPHARMA, MSD EUROPE, MILLENNIUM, MONDOBIOTECH, NEXGENIX, NOVARTIS, NPS PHARMA, OP2 DRUGS, ORFAGEN, ORPHAN EUROPE, OVID THERAPEUTICS, PFIZER, PHARMA MAR, PHARMION, PROMETIC LIFE SCIENCES, PROSENSA, PTC, RAPTOR, REGENXBIO, ROCHE, SANGAMO, SANOFI GENZYME, SANTHERA, SAREPTA, SERVIER, SHIRE, SIGMA-TAU, SIGMA-TAU, SOBI, SPARK THERAPEUTICS, SYNAGEVA, SYNEOS HEALTH, TAKEDA, THERAKOS, UCB, ULTRAGENYX, VANDA, VERTEX, VIFOR PHARMA, CYDAN, CLINIGEN, ICON, ILLUMINA, INCEPTUA, OpenApp, EUROMED-PETRONI, VITRO SOFTWARE

EURORDIS Black Pearl Award, donations in 2018
 ACTELION, ALEXION, AMICUS THERAPEUTICS, BIOGEN, CHIESI, CSL BEHRING, CYTOKINETICS, HORIZON, LEADIANT BIOSCIENCES, ORPHAN EUROPE, SOBI, Haffner Associates, MK&A, OpenApp

European Conference on Rare Diseases (ECRD) 2018
 ACHILLION, AMGEN, ASTRAZENECA, ACTELION, ALEXION, ALNYLAM, BAXTER, BAYER, BIOGEN, BIOMARIN, CELGENE, CHIESI, CSL BEHRING, SANOFI GENZYME, GSK, GSK, HELSINN, IPSEN, JANSSEN, JERINI, KYOWA KIRIN, LUNDBECK, MSD EUROPE, MILLENNIUM, NOVARTIS, ORPHAN EUROPE, PFIZER, PHARMION, PTC, RAPTOR, SANOFI GENZYME, SERVIER, SHIRE, SOBI, TAKEDA, UCB, ULTRAGENYX, VERTEX

RareConnect 2018
 CHIESI, CSL BEHRING, GSK, HORIZON, MILLENNIUM, NOVARTIS, PFIZER, RAPTOR, SHIRE

Rare Barometer 2018
 GSK, NOVARTIS, SHIRE

Rare Diseases International 2018
 CHIESI, KYOWA KIRIN, NOVARTIS, ORPHAN EUROPE, PFIZER, SANOFI GENZYME, SHIRE, VERTEX

EURORDIS International Initiatives 2018
 ALEXION, CELGENE, CSL BEHRING, PFIZER, SANOFI GENZYME, SHIRE, TAKEDA, AIPM

Rare Impact 2019
 AUDENTES, BIOMARIN, BLUEBIRD BIO, CELGENE, CHIESI, GILEAD, NOVARTIS, ORCHARD THERAPEUTICS, PFIZER, PTC, REGENXBIO, SANGAMO, SANOFI GENZYME, SAREPTA, SHIRE, SPARK THERAPEUTICS, ULTRAGENYX, VERTEX

EURORDIS Round Table of Companies (ERTC) new members in 2019
 ABEONA, AEGLEA BIOTHERAPEUTICS, ARGENX, CLEMENTIA an Ipsen Company, HANSA MEDICAL, LEO Pharma, Orchard
 Therapeutics

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Athanasiou Dimitrios
Date:	2019-11-13

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template